{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:21:12Z","timestamp":1778055672008,"version":"3.51.4"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Nasopharyngeal carcinoma is a highly aggressive malignant tumor, and research into its immunotherapy has attracted considerable attention in recent years. Imaging assessment plays a pivotal role in monitoring the efficacy of immunotherapy. Traditional evaluation methods are becoming increasingly limited in clinical applicability because of their inability to capture the spatiotemporal heterogeneity of immunotherapy responses. In this context, the development of multimodal fusion imaging techniques, radiomics, and novel probes offers new perspectives to address these challenges. These advanced and emerging technologies not only provide more comprehensive and precise anatomical, functional, and metabolic information but also enable multidimensional and in-depth data mining and analysis, thereby optimizing immunotherapy response evaluation workflows and enhancing the accuracy of efficacy predictions. Future research should focus on establishing and standardizing novel assessment systems, developing and optimizing specific molecular probes, and integrating multiomics data to advance personalized therapeutic decision-making. This narrative review retrospectively summarizes the progress in imaging assessment for nasopharyngeal carcinoma immunotherapy, spanning from the limitations of conventional methods to the application of technological innovations, and ultimately identifying optimized pathways for clinical practice, with the goal of providing a reference for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002140","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:00:27Z","timestamp":1773759627000},"page":"621-628","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Breaking the shackles of morphology: a novel perspective on immunotherapy evaluation for nasopharyngeal carcinoma using multimodal imaging and radiomics \u2013 a review"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-9661","authenticated-orcid":false,"given":"Shaoxi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"R1-20260506","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mco2.32","article-title":"Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma.","volume":"2","author":"Zhu","year":"2021","journal-title":"MedComm (2020)"},{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cac2.12619","article-title":"Targeting the LMP1-ALIX axis in EBV+ nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity.","volume":"44","author":"He","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12885-019-5689-y","article-title":"PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.","volume":"19","author":"Jiang","year":"2019","journal-title":"BMC Cancer"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.02.008","article-title":"Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians.","volume":"65","author":"Outh-Gauer","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/COC.0000000000000449","article-title":"Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in epstein-barr virus-associated nasopharyngeal carcinoma.","volume":"41","author":"Larbcharoensub","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4132\/jptm.2024.11.27","article-title":"PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17\/\u03b2-catenin in nasopharyngeal carcinoma.","volume":"59","author":"Feng","year":"2025","journal-title":"J Pathol Transl Med"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PAI.0000000000000903","article-title":"Expression of immune checkpoint regulators, cytotoxic t-lymphocyte antigen-4, and programmed death-ligand 1 in Epstein\u2013Barr virus-associated nasopharyngeal carcinoma.","volume":"29","author":"Ahmed","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.7150\/ijbs.103703","article-title":"BRD7 Inhibited immune escape in nasopharyngeal carcinoma via inhibiting PD-L1 expression.","volume":"21","author":"Guo","year":"2025","journal-title":"Int J Biol Sci"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"102428","DOI":"10.1016\/j.ctrv.2022.102428","article-title":"Clinical trial data of Anti-PD-1\/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: a review.","volume":"109","author":"Adkins","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41698-024-00558-1","article-title":"Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma.","volume":"8","author":"Ma","year":"2024","journal-title":"npj Precis Oncol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"e003790","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).","volume":"9","author":"Yang","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/cells10092458","article-title":"Radiotherapy combined with PD-1 inhibition increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells.","volume":"10","author":"Makowska","year":"2021","journal-title":"Cells"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","article-title":"Imaging biomarkers for evaluating tumor response: RECIST and beyond.","volume":"9","author":"Ko","year":"2021","journal-title":"Biomark Res"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41467-024-45276-1","article-title":"Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.","volume":"15","author":"Cao","year":"2024","journal-title":"Nat Commun"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(24)00677-6","article-title":"Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.","volume":"26","author":"Chong","year":"2025","journal-title":"Lancet Oncol"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/hed.27754","article-title":"Optimal cut-off value for identifying objective response in patients with nasopharyngeal carcinoma after induction chemotherapy.","volume":"46","author":"Luo","year":"2024","journal-title":"Head Neck"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.tranon.2022.101412","article-title":"Which evaluation criteria of the short-term efficacy can better reflect the long-term outcomes for patients with nasopharyngeal carcinoma?","volume":"20","author":"Ma","year":"2022","journal-title":"Transl Oncol"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-022-01307-2","article-title":"Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.","volume":"15","author":"Xu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-024-45126-0","article-title":"Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial.","volume":"15","author":"Liang","year":"2024","journal-title":"Nat Commun"},{"key":"R20-20260506","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s10142-023-01044-w","article-title":"KIF23, under regulation by androgen receptor, contributes to nasopharyngeal carcinoma deterioration by activating the Wnt\/\u03b2-catenin signaling pathway.","volume":"23","author":"Xu","year":"2023","journal-title":"Funct Integr Genomics"},{"key":"R21-20260506","doi-asserted-by":"crossref","first-page":"1410250","DOI":"10.3389\/fimmu.2024.1410250","article-title":"Case report: immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis.","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"R22-20260506","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-024-00601-1","article-title":"Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.","volume":"8","author":"Liu","year":"2024","journal-title":"npj Precis Oncol"},{"key":"R23-20260506","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1177\/15353702211037261","article-title":"Epstein\u2013Barr virus microRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7.","volume":"246","author":"Luo","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"R24-20260506","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1080\/15384101.2023.2293590","article-title":"PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.","volume":"22","author":"Su","year":"2023","journal-title":"Cell Cycle"},{"key":"R25-20260506","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12149-020-01537-9","article-title":"Immune microenvironment of the gene signature reflecting the standardised uptake value on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in head and neck squamous cell carcinoma.","volume":"35","author":"Han","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R26-20260506","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2967\/jnumed.117.194217","article-title":"Tumor metabolic features identified by 18F-FDG PET correlate with gene networks of immune cell microenvironment in head and neck cancer.","volume":"59","author":"Na","year":"2018","journal-title":"J Nucl Med"},{"key":"R27-20260506","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00259-019-04654-4","article-title":"Usefulness of [18F]fluorodeoxyglucose PET\/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma.","volume":"47","author":"Zhao","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20260506","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/RLU.0000000000005863","article-title":"Prognostic value of 18 F-FDG PET\/CT metabolic parameters in resectable non-small cell lung cancer treated with neoadjuvant immunotherapy plus chemotherapy.","volume":"50","author":"Cheng","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R29-20260506","doi-asserted-by":"crossref","first-page":"e2415998","DOI":"10.1001\/jamanetworkopen.2024.15998","article-title":"Stereotactic body radiotherapy and liver transplant for liver cancer: a nonrandomized controlled trial.","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R30-20260506","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hed.26583","article-title":"Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.","volume":"43","author":"Kishikawa","year":"2021","journal-title":"Head Neck"},{"key":"R31-20260506","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res"},{"key":"R32-20260506","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-023-00538-x","article-title":"Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.","volume":"23","author":"Kaira","year":"2023","journal-title":"Cancer Imaging"},{"key":"R33-20260506","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3390\/diagnostics14182104","article-title":"[18F]FDG PET\/CT Integration in evaluating immunotherapy for lung cancer: a clinician\u2019s practical approach.","volume":"14","author":"Brezun","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R34-20260506","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1007\/s00259-022-05788-8","article-title":"Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer.","volume":"49","author":"Humbert","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R35-20260506","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.3390\/cancers13236019","article-title":"Adapting imaging protocols for PET-CT and PET-MRI for immunotherapy monitoring.","volume":"13","author":"Beuthien-Baumann","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R36-20260506","doi-asserted-by":"crossref","first-page":"e000656","DOI":"10.1136\/jitc-2020-000656","article-title":"Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET\/MRI and treatment response to checkpoint inhibitor therapy?","volume":"8","author":"Seith","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R37-20260506","doi-asserted-by":"crossref","first-page":"e000349","DOI":"10.1136\/jitc-2019-000349","article-title":"Predictive value of integrated 18F-FDG PET\/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.","volume":"8","author":"Umeda","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R38-20260506","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/diagnostics14131375","article-title":"Chemokine receptor-4 Targeted PET\/ct imaging with 68ga-pentixafor in head and neck cancer-a comparison with 18F-FDG and CXCR4 Immunohistochemistry.","volume":"14","author":"Hadebe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R39-20260506","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts.","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"R40-20260506","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1007\/s00259-024-06756-0","article-title":"Diagnostic efficacy of [68Ga]Ga-DOTA-GPFAPI-04 in patients with solid tumors in a head-to-head comparison with [18F]F-FDG: results from a prospective clinical study.","volume":"51","author":"Yuan","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R41-20260506","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-014-2905-5","article-title":"(68)Ga-DOTA (0)-Tyr (3)-octreotide positron emission tomography in nasopharyngeal carcinoma.","volume":"42","author":"Schartinger","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R42-20260506","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0044-1790599","article-title":"Metachronous second primary in the form of nasopharyngeal carcinoma following treatment of small cell neuroendocrine carcinoma of the head and neck: dual tracer PET\/CT findings highlighting SSTR2 expression and its theranostic implications.","volume":"23","author":"Edamadaka","year":"2024","journal-title":"World J Nucl Med"},{"key":"R43-20260506","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2967\/jnumed.125.269585","article-title":"CD70-Targeted [18F]RCCB6 Immuno-PET\/CT imaging in patients with nasopharyngeal carcinoma: a proof-of-concept study.","volume":"66","author":"Shi","year":"2025","journal-title":"J Nucl Med"},{"key":"R44-20260506","first-page":"686","article-title":"PD-L1 PET\/CT imaging with radiolabeled durvalumab in patients with advanced-stage non-small cell lung cancer.","volume":"63","author":"Smit","year":"2022","journal-title":"J Nucl Med"},{"key":"R45-20260506","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1021\/acs.jmedchem.3c02342","article-title":"Development and in vivo evaluation of small-molecule ligands for positron emission tomography of immune checkpoint modulation targeting programmed cell death 1 ligand 1.","volume":"67","author":"Bamminger","year":"2024","journal-title":"J Med Chem"},{"key":"R46-20260506","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11307-023-01889-4","article-title":"Development, characterization, and radiation dosimetry studies of 18F-BMS-986229, a 18F-labeled PD-L1 macrocyclic peptide PET tracer.","volume":"26","author":"Kim","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"R47-20260506","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2967\/jnumed.123.267186","article-title":"18F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer.","volume":"65","author":"Cytryn","year":"2024","journal-title":"J Nucl Med"},{"key":"R48-20260506","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11307-020-01544-2","article-title":"In vivo evaluation and dosimetry estimate for a high affinity affibody PET tracer targeting PD-L1.","volume":"23","author":"Rubins","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"R49-20260506","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1039\/D0CB00070A","article-title":"Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint.","volume":"1","author":"Hu","year":"2020","journal-title":"RSC Chem Biol"},{"key":"R50-20260506","doi-asserted-by":"crossref","first-page":"1401515","DOI":"10.3389\/fmed.2024.1401515","article-title":"Navigating the landscape of PD-1\/PD-L1 imaging tracers: from challenges to opportunities.","volume":"11","author":"Badenhorst","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R51-20260506","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2967\/jnumed.119.241364","article-title":"Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer 18F-BMS-986192.","volume":"61","author":"Stutvoet","year":"2020","journal-title":"J Nucl Med"},{"key":"R52-20260506","doi-asserted-by":"crossref","first-page":"698425","DOI":"10.3389\/fonc.2021.698425","article-title":"Molecular imaging and the PD-L1 pathway: from bench to clinic.","volume":"11","author":"Leung","year":"2021","journal-title":"Front Oncol"},{"key":"R53-20260506","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s00259-020-04756-4","article-title":"Effect of machine learning re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients.","volume":"47","author":"Xie","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R54-20260506","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1109\/JBHI.2022.3181791","article-title":"DeepMTS: deep multi-task learning for survival prediction in patients with advanced nasopharyngeal carcinoma using pretreatment PET\/CT.","volume":"26","author":"Meng","year":"2022","journal-title":"IEEE J Biomed Health Inform"},{"key":"R55-20260506","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1007\/s00259-023-06399-7","article-title":"Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma.","volume":"50","author":"Gu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R56-20260506","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/diagnostics14090924","article-title":"Deciphering the prognostic efficacy of MRI radiomics in nasopharyngeal carcinoma: a comprehensive meta-analysis.","volume":"14","author":"Wang","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R57-20260506","doi-asserted-by":"crossref","first-page":"e39302","DOI":"10.1097\/MD.0000000000039302","article-title":"A systematic review of the predictive value of radiomics for nasopharyngeal carcinoma prognosis.","volume":"103","author":"Deng","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R58-20260506","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21147\/j.issn.1000-9604.2025.02.01","article-title":"Integrated clinical-radiomic model for predicting treatment response of concurrent chemo-radiotherapy and radiotherapy alone in controversial subgroup of AJCC\/UICC ninth edition stage I nasopharyngeal cancer.","volume":"37","author":"Ng","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"R59-20260506","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0658","article-title":"Early prediction of death risk in progressive nasopharyngeal carcinoma using radiomics nomogram based on clinical semantic multi-parameter magnetic resonance imaging.","volume":"86","author":"Xi","year":"2025","journal-title":"Br J Hosp Med (Lond)"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:01:07Z","timestamp":1778054467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002140","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}